Advertisement
Canada markets closed

  • S&P/TSX

    22,011.72
    +139.76 (+0.64%)
     

  • S&P 500

    5,070.55
    +59.95 (+1.20%)
     

  • DOW

    38,503.69
    +263.71 (+0.69%)
     

  • CAD/USD

    0.7320
    +0.0018 (+0.25%)
     

  • CRUDE OIL

    83.31
    +1.41 (+1.72%)
     

  • Bitcoin CAD

    90,517.06
    -439.38 (-0.48%)
     

  • CMC Crypto 200

    1,430.71
    +15.95 (+1.13%)
     

  • GOLD FUTURES

    2,335.70
    -10.70 (-0.46%)
     

  • RUSSELL 2000

    2,004.44
    +36.97 (+1.88%)
     

  • 10-Yr Bond

    4.5980
    -0.0250 (-0.54%)
     

  • NASDAQ

    15,696.64
    +245.33 (+1.59%)
     

  • VOLATILITY

    15.83
    -1.11 (-6.55%)
     

  • FTSE

    8,044.81
    +20.94 (+0.26%)
     

  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     

  • CAD/EUR

    0.6837
    -0.0013 (-0.19%)
     
MARKETS LIVE BLOG:

S&P 500, NASDAQ NOTCH BIG WINS WITH TESLA EARNINGS ON DECK

Tech-focused investors prepare for fresh wave of earnings highlighted by struggling Tesla

AbbVie’s Rova-T: Can Label Expansion Make It a Blockbuster Drug?

Margaret Patrick
Updated
AbbVie’s Rova-T: Can Label Expansion Make It a Blockbuster Drug?

The company will be launching its Phase 3 TAHOE study to compare Rova-T with topotecan, the only therapy in second line SCLC approved by the FDA (U.S. Food & Drug Administration). AbbVie also aims to establish the importance of targeting tumor-initiating cells in treating solid tumors. Beyond 2020, the company plans to launch the MERU study, which will enable Rova-T to expand its label in the first line SCLC maintenance indication.

Continue reading